GSKIP activators belong to a class of chemical compounds that are characterized by their ability to enhance the activity of Glycogen Synthase Kinase 3β Interaction Protein (GSKIP). GSKIP is a protein known to interact with Glycogen Synthase Kinase 3β (GSK-3β), a kinase involved in various cellular processes including metabolism, neuronal function, and cellular structure maintenance. The GSKIP protein modulates the activity of GSK-3β by acting as an intracellular mediator. Activators of GSKIP are designed to upregulate the function of GSKIP, resulting in an alteration of the GSK-3β signaling cascade. These chemicals typically exert their effect by binding to GSKIP, thereby stabilizing it, or by enhancing its interaction with GSK-3β, leading to a change in the latter's activity. The nature of the interaction between GSKIP activators and the GSKIP protein is critical, and it requires a precise understanding of the protein's structure and the associated signaling pathways. The development of these activators involves detailed studies of the binding sites and conformational changes of GSKIP that are necessary for its function, to create molecules that effectively modulate its activity.
The synthesis of GSKIP activators is a sophisticated endeavor that combines elements of organic chemistry, molecular biology, and pharmacology. It begins with the identification of potential lead compounds that can interact with GSKIP. These leads are often discovered through high-throughput screening or found in known molecules with related activity. Once a potential activator is identified, it undergoes a series of chemical modifications aimed at optimizing its interaction with GSKIP. This optimization process involves tweaking the molecular structure of the activator, such as adjusting functional groups or altering the backbone of the molecule to enhance its binding affinity and selectivity for GSKIP. Researchers use structure-activity relationship (SAR) studies to systematically investigate the impact of these modifications, guiding adjustments to improve the efficacy of the activator.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid can inhibit GSK3B and HDACs, affecting multiple signaling pathways including Wnt/β-catenin signaling. As GSKIP interacts with GSK3B, the inhibition of GSK3B by valproic acid may enhance the activity of GSKIP. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
This compound is a GSK3B inhibitor that may lead to enhanced GSKIP function due to the close interaction between GSKIP and GSK3B. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone, another member of the paullones, inhibits GSK3B and can lead to altered Wnt/β-catenin signaling dynamics, potentially affecting GSKIP activity. | ||||||